Introduction
============

Sprint interval training (SIT) is a time-efficient method of providing cardiorespiratory and muscular adaptations with a lower training volume ([@B20]), in addition to which, it has also recently been suggested as an additional tool in the treatment of disease ([@B20]). However, execution of this mode of training seems to be associated with a higher possibility of damage and inflammatory processes in muscular tissue, evidenced by increases in systemic biochemical markers and cytokine concentrations ([@B3]; [@B21]). Considering that during training planning, interest in the monitoring/measurement of the recovery status is growing (i.e., measurement of responses of autonomic nervous system by heart rate variability, training impulse, or RPE-session) with a focus on choosing the ensuring training load/stress ([@B22]), the use of recovery modalities after exercise, aiming to speed up the process of tissue repair, may be a valid strategy to associate with SIT sessions ([@B5]).

Traditionally, active recovery (AR) and cold-water immersion (CWI) have been widely used to accelerate muscular recovery after intense exercise sessions ([@B5]). However, despite their popularity, the beneficial effects of CWI and AR have recently been questioned ([@B5]; [@B33]). In this way, photobiomodulation therapy (PBMT), a type of light therapy that utilizes non-ionizing and non-thermal light sources in the visible and infrared spectrum, eliciting photophysical and photochemical events on biological tissue ([@B2]), has attracted attention in the area of sports and health sciences. Some isolated studies have suggested its effects in reducing muscle damage markers ([@B6]; [@B12]; [@B15]), attenuating or anticipating inflammatory responses ([@B1]; [@B36]), and reducing some symptoms of inflammation such as delayed onset muscle soreness (DOMS) and loss of muscle function ([@B8]). However, despite these findings, the effects of PBMT on overall human muscle recovery (i.e., considering perceptive, physiological, and functional aspects) are contradictory and the actual effectiveness remains uncertain.

The majority of studies with PBMT have investigated its effects using isolated contractions and exercise-induced muscle damage protocols ([@B6]; [@B8]; [@B15]), and only a few after a common high-intensity exercise session such as SIT. Additionally, some studies have compared the effects of PBMT with cryotherapy methods ([@B15]; [@B13]), however, without precise temperature control, a determinant parameter for its effectiveness ([@B26]), and no studies have compared PBMT with an AR protocol, a widely used method after exercise sessions. The possible beneficial effects of PBMT on overall muscle recovery may contribute to fortifying this method as an additional tool in the exercise routine.

Therefore, the aim of the present study was to investigate the effectiveness of PBMT on muscle recovery in view of systemic inflammation (interleukin-10 \[IL-10\] and tumor necrosis factor-α \[TNFα\]), muscle damage (creatine kinase \[CK\] and lactate dehydrogenase \[LDH\]), DOMS, and muscle performance (countermovement jump performance \[CMJ\]) after SIT, and to compare PBMT with AR and CWI interventions. The hypothesis of the study was that PBMT would decrease CK and LDH blood concentrations, accelerate systemic inflammatory responses, and reduce DOMS and loss in CMJ performance.

Materials and Methods {#s1}
=====================

The study was conducted in two parts. Part-I was performed to compare the PBMT with the placebo (PLA) condition in a double-blind design, while part-II aimed to compare PBMT with AR and CWI with parallel groups.

Participants
------------

The minimum sample size for a statistical power of 90 % (alpha: 0.05; allocation ratio: 1) was 10 participants in each group. The sample size was calculated based on the findings of [@B14], using the TNFα results and assuming an effect size of 1.4 (*d* value). Thus, a total of thirty-six healthy men participated in the present investigation, of which twelve participated in both part-I and part-II, with an addition of twenty-four volunteers in part-II (i.e., total of thirty-six in part-II, allocated into three groups of twelve participants each).

Prior to beginning the study, volunteers were informed about the procedures, risks, and benefits involved in the tests and then signed the consent form. All experimental procedures were approved by the Human Research Ethics Committee from the School of Sciences, São Paulo State University -- UNESP (protocol number: 1.139.070) and conducted in accordance with the Declaration of Helsinki.

Participants were untrained, healthy individuals, without any vascular disease, metabolic disorders, recent muscle-skeletal or joint injuries (i.e., in the previous 6 months), and had not used nutritional or pharmacological substances for at least 3 months. Volunteers who were regularly absent from the trials, initiated the use of nutritional and/or pharmacological substances during the evaluations, or presented muscle injury were excluded from the study.

Experimental Design
-------------------

Participants arrived at the laboratory in the morning after fasting (≈8-h). One hour before the evaluations an individual breakfast was offered to the volunteers composed of 30% of daily caloric expenditure ([@B28]).

The graded exercise test (GXT) and SIT were performed on an electromagnetic cycle ergometer (Excalibur Sport, Lode, Netherlands). Before all tests, a 5-min warm-up at 30% of the maximal aerobic power (MAP) reached in the GXT was performed.

The study was divided into two sequenced and dependent parts (I and II).

Part-I was conducted in a double-blind, randomized, and placebo-controlled design. Firstly, a GXT was performed to determine the peak oxygen uptake (![](fphys-09-01948-i001.jpg)O~2peak~) and the MAP. Five days after the GXT, two SIT sessions (SIT~1~ and SIT~2~) were performed, interspaced by 24-h of recovery (double SIT), to potentiate the stress on active muscle. The double SIT (i.e., set of 2 SIT sessions) was performed twice before each experimental condition (i.e., PBMT and placebo), separated by 5-days. Immediately after the double SIT (i.e., only post the SIT~2~), PBMT was applied in mode on (PBMT condition -- C~PBMT~) or off (PLA condition -- C~PLA~) in randomized and counterbalanced order. To ensure blinding in each experimental condition, participants were blindfolded and wore headphones to eliminate light and sound signals. A person not involved in any parts of the study applied the PBMT and randomization.

Part-II was conducted as a parallel-group trial, with GXT and SIT sessions identical to those reported in part-I; however, immediately after the double SIT (i.e., only post SIT~2~), the recovery interventions were composed of active recovery (AR; group AR -- G~AR~) or cold-water immersion (CWI; group CWI- G~CWI~). Posteriorly, the C~PBMT~ data recorded from part-I were used to compare with G~AR~ and G~CWI~ in part-II.

Venous blood sample collections were realized in the medial cubital vein at rest (i.e., baseline) and 0.5, 1, 24, 48, and 72-h after each recovery condition (part-I) or intervention (part-II) using vacutainer tubes of 10 and 4 mL (BD, Juiz de Fora, MG, Brazil) for inflammatory and muscle damage marker measurements. Capillary blood samples (25 μL) were collected from the earlobe 3, 5, and 7-min after GXT, and before, between intervals (i.e., 3rd-min after each Wingate test) and 5 and 7-min after each SIT session for measurement of lactate concentrations.

In parts I and II, CMJ performance and DOMS were evaluated at rest (i.e., baseline), and 24, 48, and 72-h after interventions.

Figure [1](#F1){ref-type="fig"} presents the experimental design of studies-I and II.

![Experimental design of studies I and II. DOMS, delay onset muscle soreness; CMJ, countermovement jump; PBMT, photobiomodulation therapy; CWI, cold-water immersion; AR, active recovery; PLA, placebo; GXT, graded exercise test; 2 × SIT, double sprint interval training.](fphys-09-01948-g001){#F1}

Graded Exercise Test
--------------------

Graded exercise test was performed to determine the ![](fphys-09-01948-i001.jpg)O~2peak~ and MAP, starting at 75 W, with a 25 W increment every 2-min until exhaustion ([@B23]; [@B29]), measured at 670-m above sea level. During GXT, respiratory responses were registered breath-by-breath using a gas analyzer (Quark CPET, COSMED, Italy), previously calibrated in accordance with the manufacturer's instructions. Data were smoothed every 10-points and interpolated every 1-s using the software OriginPro 8.0 (OriginLab Corporation, United States). For ![](fphys-09-01948-i001.jpg)O~2peak~ determination, the oxygen uptake (![](fphys-09-01948-i001.jpg)O~2~) mean of the final 20-s of each stage was determined and the ![](fphys-09-01948-i001.jpg)O~2peak~ was assumed as the highest ![](fphys-09-01948-i001.jpg)O~2~ mean reached in the GXT. MAP was recorded and considered the highest exercise power performed during the test.

Sprint Interval Training Session
--------------------------------

The double SIT comprised two SIT sessions interspaced by 24-h, mimicking the accumulated effects of two consecutive training days. Each SIT constituted four Wingate tests (i.e., 30-s at 0.7 Nm⋅kg^-1^) with a 4-min recovery between bouts ([@B9]). In the first minute of recovery time an active recovery at 30% of MAP and ≈75--80 rpm was performed to minimized is comfort, while the additional recovery time (i.e., 3-min) was composed of passive recovery ([@B20]). The SIT protocol was controlled using Wingate 1.11 software (Lode, Netherlands) which enabled measurement of bout work (BW), peak power (PP), and mean power (MP). Workload performed during the double SIT was assumed as the sum of all work performed during the Wingate tests (total work -- TT). In a previous study performed in our laboratory, the SIT showed good reliability of TT 7-days after a first session (ICC = 0.89) ([@B27]). The SIT performance parameters were measured to ensure that the volunteers were submitted to the same exercise effort in both study parts.

CMJ and DOMS Measurements
-------------------------

To evaluate the symptoms of inflammation (i.e., muscle functional limitation and DOMS), the CMJ and DOMS were measured. CMJ was composed of 3 maximal jump trials interspaced by 1-min of passive recovery. Volunteers were instructed to remain with hands on hips and flex the knees quickly to 90° to jump. To assess the jump height, a jump platform was used (Jump test, Cefise, Brazil) and the highest jump was considered. This configuration of CMJ test was chosen as it does not influence blood cytokines or muscle damage markers. In addition, DOMS perception was assessed using a VAS consisting of a 100 mm line, on which the "0" represents "no pain" and "100" "very painful" ([@B10]). For greater leg pain perception, the scale was applied during low-intensity pedaling ([@B8]). In the present study, CMJ and DOMS values are presented as change related to baseline (Δ), being described using the variable acronym plus the "Δ" (i.e., CMJ^Δ^ and DOMS^Δ^).

Recovery Methods
----------------

Photobiomodulation therapy was applied using a cluster multi-diode containing 104 LED (THOR-LX2, THOR Photomedicine Ltd., United Kingdom). The PBMT protocol had an overall duration of 2.5-min, with application in both legs simultaneously. LED irradiation was performed in two regions of the quadriceps muscle, two regions of the biceps femoris, and one region between the soleus and gastrocnemius muscles, following the distribution axis of the muscle fibers. The interventions were performed using the spot method, with direct contact (i.e., 90° angle) of the equipment on the skin surface. The technical parameters of PBMT and location of LED irradiation are shown in Figure [2](#F2){ref-type="fig"}.

![Technical parameters of PBMT and location of LED irradiation. LED, light emitting diode.](fphys-09-01948-g002){#F2}

Active recovery and CWI were applied only in part-II. AR was performed on a cycle ergometer, immediately after the double SIT, with a duration of 15-min and intensity corresponding to 50% of MAP ([@B35]). During AR, a cadence of ≈75 rpm was maintained. The partial CWI, to the waist, was performed immediately after the double SIT with the volunteers sitting in an immersion bath containing 200 L of water, at 10°C for 10-min ([@B26]). The temperature was set using an auto-cooling system, controlled by a digital thermostat (TIC17RGTi, ES Full Gauge, United States), triggered when the water temperature increased 0.1°C.

Blood Sample Analysis
---------------------

Capillary blood samples were deposited into microtubes containing 50 μL of sodium fluoride at 1% and analyzed in an electrochemical analyzer (YSI 2300 Stat Plus, Yellow Springs Instruments, United States) for determination of lactate concentrations. According to the manufacturer, the equipment has a measurement error of ±2%.

Venous blood samples were centrifuged for 10-min at 1306 *g* and 4°C (Vision scientific, VS-15000FNII, SKR) for extraction of plasma and serum. Plasmatic cytokines (IL-10 and TNFα) were assessed using ELISA commercial kits (Affymetrix, eBioscience, United States; Lot: IL-10 4295480; TNFα 4298657). Plates were read using a spectrophotometer, SpectraMax Plus 384 (Molecular Devices, United States). Serum CK and LDH concentrations were assessed through a kinetic method using a random-access analyzer (A-15, Biosystems S.A., Spain) and commercial kits (Biosystems S.A., Spain; Lot: CK 13869; LDH 09998).

Considering the great individual variation in CK, LDH, IL-10, and TNFα blood concentrations, in the present study the blood markers are presented as percentage difference to baseline (Δ%), being described using the variable abbreviation plus the "Δ%" (i.e., CK^Δ%^, LDH^Δ%^, IL-10^Δ%^, and TNFα^Δ%^). The integrals of CK, LDH, IL-10, and TNFα (i.e., area under the curve considering its concentration and the evaluation time) were calculated using the software OriginPro 8.0 (OriginLab Corporation, United States) to test whether exposure to inflammation and muscle damage were affected by recovery methods ([@B25]). In addition, peak concentration of CK, LDH, IL-10, and TNFα (i.e., highest value obtained between 0.5 and 72-h) were calculated to measure the magnitude of increase.

Statistical Analysis
--------------------

Statistical analyses were performed using the software package SPSS version 23.0 (IBM Corp., Armonk, NY, United States). Data are presented as means and standard deviations (mean ± SD). The normality of the data was confirmed using the Shapiro-Wilk test. In both parts (e.g., I and II), to compare the CK^Δ%^, LDH^Δ%^, IL-10^Δ%^, and TNFα^Δ%^ blood concentrations, DOMS^Δ^ and CMJ^Δ^ performance between moments (i.e., main time effect) and between and within-conditions and groups (i.e., interaction time^∗^groups) a two-way repeated measure ANOVA was used and a SIDAK *post hoc* was applied when necessary. Mauchly's sphericity test was used in all ANOVA analyzes, and in cases of sphericity violation, the F and significance corrected by Greenhouse-Geisser were assumed. Only in part-I, the paired *t*-test was used to compare the means of SIT total work, integral, and peak blood concentration of CK^Δ%^, LDH^Δ%^, IL-10^Δ%^, and TNFα^Δ%^ (i.e., C~PBMT~ × C~PLA~). In addition, the *t*-test was also used to compare peak lactate concentrations which were measured two times for each condition (i.e., C~PBMT~ SIT~1~ × SIT~1~ C~PLA~ and C~PBMT~ SIT~2~ × SIT~2~ C~PLA~). In part-II, the ANOVA one-way test was used to compare peak lactate concentrations, MAP, ![](fphys-09-01948-i001.jpg)O~2peak~, and integral and peak blood markers between groups (i.e., C~PBMT~, G~AR~, and G~CWI~). In both parts (e.g., I and II), SIT total work and peak lactate concentration were compared to verify similar exercise-induced workload and metabolic stress. In all cases, a significance level of 5% was assumed.

Results
=======

Part-I and II: GXT and SIT Outcomes
-----------------------------------

In part-I, the ![](fphys-09-01948-i001.jpg)O~2peak~ and MAP reached in the GXT were 40.0 ± 5.7 mL⋅kg^-1^⋅min^-1^ and 210.4 ± 29.1 W, respectively. The double SIT total work (i.e., SIT~1~ and SIT~2~ work sum) for C~PBMT~ and C~PLA~ were 96.4 ± 13.4 and 99.5 ± 13.9 kJ, respectively. In addition, the peak lactate concentrations reached in SIT for C~PBMT~ and C~PLA~ were 14.1 ± 2.7 and 14.4 ± 2.0 (SIT~1~), 13.9 ± 2.9, and 14.2 ± 2.0 mmol⋅L^-1^ (SIT~2~), respectively. No differences between C~PLA~ and C~PBMT~ were verified in double SIT total work \[*P* = 0.941, *t*~(11)~ = -0.075\] or peak lactate concentration reached after SIT sessions \[SIT~1~: *P* = 0.479, *t*~(9)~ = -0.738; SIT~2~: *P* = 0.666; *t*~(11)~ = -0.444\].

In part-II, there were no significant differences between the anthropometric characteristics of the volunteers \[*P* ≥ 0.136; *F*~(2,33)~ ≤ 2.123\] (Table [1](#T1){ref-type="table"}). The ![](fphys-09-01948-i001.jpg)O~2peak~ reached in GXT for G~AR~ and G~CWI~ were 41.9 ± 5.0, 38.1 ± 6.5 mL⋅kg^-1^⋅min^-1^, while MAP values were 218.8 ± 45.4 and 214.6 ± 45.8 W, respectively. No significant differences were verified between groups (i.e., C~PBMT~, G~AR~, and G~CWI~) in ![](fphys-09-01948-i001.jpg)O~2peak~ \[*P* = 0.306; *F*~(2,33)~ = 1.229\] and MAP \[*P* = 0.883; *F*~(2,33)~ = 0.125\] reached in the GXT. The SIT total work for G~AR~ and G~CWI~ were 103.1 ± 25.8, and 99.6 ± 21.8 kJ. In addition, the peak lactate concentrations reached in SIT for G~AR~ and G~CWI~ were 14.7 ± 1.2 and 14.3 ± 0.9 mmol⋅L^-1^ (SIT~1~), and 14.0 ± 1.4 and 13.5 ± 1.4 mmol⋅L^-1^ (SIT~2~), respectively. No differences between C~PBMT~, G~AR~, and G~CWI~ were verified in double SIT total work \[*P* = 0.874; *F*~(2,33)~ = 135\] and peak lactate concentration reached after the SIT session \[SIT~1~: *P* = 0.859; *F*~(2,31)~ = 0.152 and SIT~2~: *P* = 0.889; *F*~(2,33)~ = 0.118\].

###### 

Anthropometric characteristics of the volunteers.

                  Part-I         Part-II        ANOVA one-way                   
  --------------- -------------- -------------- --------------- ------- ------- -------
  Age (years)       25.7 ± 5.1     23.7 ± 4.4     24.2 ± 5.5    0.606   0.509   2, 33
  Height (cm)     177.3 ± 3.0    175.5 ± 4.1    179.7 ± 7.0     0.229   1.541   2, 33
  Weight (kg)       76.3 ± 7.4     73.9 ± 7.8     73.6 ± 10.0   0.597   0.524   2, 33
  BMI (kg/m^2^)     24.2 ± 1.7     25.4 ± 4.2     22.8 ± 2.9    0.136   2.123   2, 33
                                                                                

G

CWI

, group submitted to cold-water immersion; G

AR

, group submitted to active recovery; BMI, body mass index; Df, degrees of freedom.

Additional performance parameters (i.e., BW, PP, and MP) and lactate kinetics before and during, and the peak reached after double SIT sessions for parts I and II are shown in Supplementary Figures [S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}, respectively.

Part-I: Recovery Outcomes
-------------------------

There was a time effect showing kinetic changes in some blood markers, independent of the treatment, but no effect for TNFα^Δ%^ blood concentration \[*P* = 0.668; *F*~(4,32)~ = 0.324\]. The LDH^Δ%^ increased at 0.5-h compared to 24, 48, and 72-h \[*P* = 0.000; *F*~(4,36)~ = 7.035; *post hoc* *P* ≤ 0.030\]. The CK^Δ%^ decreased over time at 72-h compared with 0.5-h \[*P* = 0.043; *F*~(4,40)~ = 2.716; *post hoc* *P* = 0.021\]. The IL-10^Δ%^ also decreased over time at 24 and 72-h compared with 1-h \[*P* = 0.035; *F*~(4,40)~ = 3.944; *post hoc* *P* ≤ 0.048\]. Contrarily, there were no interactions (i.e., interaction time^∗^groups) between C~PBMT~ and C~PLA~ for any blood markers \[*P* ≥ 0.313; *F*~(4,32)~ ≤ 1.327\] (Figure [3](#F3){ref-type="fig"}). The part-I absolute values of CK, LDH, IL-10, and TNFα blood concentrations are presented in Supplementary Table [S1](#SM5){ref-type="supplementary-material"}.

![Blood concentration of IL-10^Δ%^, TNFα^Δ%^, CK^Δ%^, and LDH^Δ%^ (mean ± SD) for C~PBMT~ and C~PLA~. IL-10^Δ%^, interleukin 10 expressed as percentage difference to baseline; TNFα^Δ%^, tumor necrosis factor alpha expressed as percentage difference to baseline; CK^Δ%^, creatine kinase expressed as percentage difference to baseline; LDH^Δ%^, lactate dehydrogenase expressed as percentage difference to baseline; C~PBMT~, photobiomodulation therapy condition; C~PLA~, placebo condition.](fphys-09-01948-g003){#F3}

Table [2](#T2){ref-type="table"} presents the peak and integral values of CK^Δ%^, LDH^Δ%^, IL-10^Δ%^, and TNFα^Δ%^ reached in C~PBMT~ and C~PLA~. For all blood markers, there were no significant differences between C~PBMT~ and C~PLA~ for peak \[*P* ≥ 0.104; *t*~(11)~ = -1.774\] or integral values \[*P* ≥ 0.370; *t*~(8)~ = -0.950\].

###### 

Comparison between C~PBMT~ and C~PLA~ for peak and integral values of CK, LDH, IL-10, and TNFα.

          C~PLA~         C~PBMT~           *t*-test                                                                 
  ------- -------------- ----------------- --------------- ----------------- ---------------- ---- ---------------- ----
  CK      170.6 ± 81.0   8330.5 ± 3308.6   139.7 ± 40.7    7902.5 ± 2170.3   0.10 (--1.774)   10   0.47 (--0.756)   10
  LDH     132.1 ± 32.6   7442.6 ± 1469.7   129.1 ± 23.2    7427.3 ± 1332.8   0.28 (--0.358)   10   0.93 (--0.091)   9
  IL-10   172.9 ± 70.2   8314.5 ± 2648.1   184.5 ± 110.7   7956.7 ± 2642.4   0.75 (0.323)     10   0.72 (--0.370)   10
  TNFα    127.1 ± 57.5   6687.8 ± 1169.0   111.3 ± 23.1    6498.7 ± 983.0    0.29 (--1.119)   9    0.37 (--0.950)   8
                                                                                                                    

IL-10, interleukin 10; TNFα, tumor necrosis factor alpha; CK, creatine kinase; LDH, lactate dehydrogenase; C

PBMT

, condition photobiomodulation therapy; C

PLA

, condition placebo; Δ%, percentage alteration related to baseline;Δ%⋅h, percentage alteration related to baseline per hour; Df, degrees of freedom.

For DOMS^Δ^, a time effect was found for DOMS^Δ^ that decreased at 72-h compared with 24-h \[*P* = 0.012; *F*~(2,22)~ = 7.263; *post hoc* *P* = 0.043\], however, there were no interactions (i.e., interaction time^∗^groups) between C~PBMT~ and C~PLA~ at the same moments as for DOMS^Δ^ \[*P* = 0.052; *F*~(2,22)~ = 4.298\] and for CMJ^Δ^ \[*P* = 0.295; *F*~(2,22)~ = 1.289\] (Figure [4](#F4){ref-type="fig"}).

![DOMS^Δ^ performance and DOMS^Δ^ for G~PBMT~ and G~PLA~ at 24, 48, and 72-h after double SIT session. DOMS^Δ^, delay onset muscle soreness expressed as difference to baseline; CMJ^Δ^, countermovement jump performance expressed as difference to baseline; C~PBMT~, condition photobiomodulation therapy; C~PLA~, condition placebo.](fphys-09-01948-g004){#F4}

Part-II: Recovery Outcomes
--------------------------

A time effect was found for CK^Δ%^ and IL-10^Δ%^, but not for LDH^Δ%^ and TNFα^Δ%^ blood concentrations. CK^Δ%^ increased at 0.5, 1, and 48-h compared with 72-h, and increased at 0.5-h compared with 24-h \[*P* = 0.003; *F*~(8,104)~ = 5.393; *post hoc* *P* ≤ 0.023\]. In addition, IL-10^Δ%^ increased over time at 1-h compared with 24 and 48-h \[*P* = 0.003; *F*~(8,108)~ = 7.568; *post hoc* *P* = 0.048\]. However, there were no interactions (i.e., interaction time^∗^groups) between C~PBMT~, G~AR~, and G~CWI~ for all markers at the same moments \[*P* ≥ 0.189; *F*~(8,80)~ ≤ 1.568\] (Figure [5](#F5){ref-type="fig"}). The part-II absolute values of CK, LDH, IL-10, and TNFα blood concentrations are presented in Supplementary Table [S2](#SM6){ref-type="supplementary-material"}.

![Blood concentration of IL-10^Δ%^, TNFα^Δ%^, CK^Δ%^, and LDH^Δ%^ (mean ± SD) for C~PBMT~, G~AR~, and G~CWI~. IL-10^Δ%^, interleukin 10 expressed as percentage difference to baseline; TNFα^Δ%^, tumor necrosis factor alpha presented as percentage difference to baseline; CK^Δ%^, creatine kinase expressed as percentage difference to baseline; LDH^Δ%^, lactate dehydrogenase expressed as percentage difference to baseline; C~PBMT~, condition photobiomodulation therapy; G~CWI~, group submitted to cold-water immersion; G~AR~, group submitted to active recovery.](fphys-09-01948-g005){#F5}

Table [3](#T3){ref-type="table"} presents the peak and integral values of CK^Δ%^, LDH^Δ%^, IL-10^Δ%^, and TNFα^Δ%^ reached in C~PBMT~, G~AR~, and G~CWI~. For all blood markers, there were no significant differences between C~PBMT~, G~AR~, and G~CWI~ for peak \[*P* ≥ 0.193; *F*~(2,31)~ ≤ 1.734\] and integral values \[*P* ≥ 0.224; *F*~(2,28)~ ≤ 1.578\].

###### 

Comparison between C~PBMT~, G~CWI~, and G~AR~ for peak and integral values of CK, LDH, IL-10, and TNFα.

          C~PBMT~         G~CWI~            G~AR~           ANOVA one-way                                                                              
  ------- --------------- ----------------- --------------- ------------------ --------------- ----------------- -------------- ------- -------------- -------
  CK      139.7 ± 40.7    7902.5 ± 2170.3   162.8 ± 78.5    8316.5 ± 3627.9    157.7 ± 94.3    8560.5 ± 5189.3   0.74 (0.310)   2, 26   0.93 (0.079)   2, 32
  LDH     129.1 ± 23.2    7427.3 ± 1332.8   146.9 ± 46.1    7869.8 ± 1536.9    185.0 ± 113.4   7995.2 ± 2470.1   0.19 (1.734)   2, 31   0.78 (0.781)   2, 25
  IL-10   184.5 ± 110.7   7956.7 ± 2642.4   219.2 ± 139.1   10112.2 ± 3580.7   185.9 ± 93.8    7672.1 ± 3857.5   0.72 (0.338)   2, 32   0.22 (1.578)   2, 28
  TNFα    111.3 ± 23.1    6498.7 ± 983.0    127.9 ± 38.6    7044.5 ± 1623.8    127.3 ± 50.8    7650.0 ± 2019.0   0.56 (0.587)   2, 30   0.32 (1.202)   2, 26
                                                                                                                                                       

IL-10, interleukin 10; TNFα, tumor necrosis factor alpha; CK, creatine kinase; LDH, lactate dehydrogenase; C

PBMT

, condition photobiomodulation therapy; G

CWI

, group submitted to cold-water immersion; G

AR

, group submitted to active recovery; Δ%, percentage alteration related to baseline; Δ%⋅h, percentage alteration related to baseline per hour; Df, degrees of freedom.

Similar results were found for DOMS^Δ^ and CMJ^Δ^. There was a time effect for DOMS^Δ^ \[i.e., DOMS^Δ^ decreased at 48 and 72-h compared with 24-h\] \[*P* = 0.001; *F*~(4,62)~ = 11.478; *post hoc* *P* ≤ 0.005\], but not for CMJ^Δ^ \[*P* = 0.253; *F*~(4,62)~ = 1.404\], while no interaction was found between groups for either parameter \[*P* = 0.314; *F*~(4,62)~ = 1.215 and *P* = 0.264; *F*~(4,62)~ = 1.343, respectively\] (Figure [6](#F6){ref-type="fig"}).

![DOMS^Δ^ performance and DOMS^Δ^ for C~PBMT~, G~AR~, and G~CWI~ at 24, 48, and 72-h after double SIT session. DOMS^Δ^, delay onset muscle soreness expressed as difference to baseline; CMJ^Δ^, countermovement jump performance expressed as difference to baseline; C~PBMT~, condition photobiomodulation therapy; G~CWI~, group submitted to cold-water immersion; G~AR~, group submitted to active recovery.](fphys-09-01948-g006){#F6}

All raw data of inflammation and muscle damage markers, delayed onset muscle soreness, and countermovement jump performance are shown in Supplementary Data Sheet [S1](#SM7){ref-type="supplementary-material"}.

Discussion
==========

Some recovery strategies have been used to accelerate muscle recovery in sport routines ([@B5]), however, despite their wide use, several doubts remain in the literature about the effectiveness of these methods. To the best of our knowledge, this is the first study to investigate the effects of PBMT on muscle recovery before SIT sessions using systemic blood markers, muscle performance, and DOMS, and compare it with CWI and AR. The main finding of the current study was the lack of effect of PBMT on muscle recovery compared with C~PLA~, as well as the fact that PBMT did not demonstrate better effects than AR or CWI. Therefore, our initial hypothesis was refuted. The time effects found (Supplementary Figures [S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}) in the current study only show changes in variable behavior independent of the experimental treatment and therefore do not demonstrate effectivity of any isolated intervention.

Initially, it should be mentioned that there were no differences in workload or metabolic stress induced by the double SIT session in both studies (I and II), indicating that all volunteers presented similar damage induction in all conditions. Consequently, the double SIT elicited increases in CK (≈57%), LDH (≈42%), IL-10 (≈86%), and TNFα (≈24%) blood concentrations in both studies and this increase was not different between conditions.

The process of muscle recovery may be monitored through systemic inflammatory marker kinetics such as cytokines (e.g., interleukins), and is usually accompanied by a decrease in muscle exercise performance and an increase in DOMS ([@B30]). Interleukins such as IL-10 and TNFα play an important role in the muscle recovery process and their concentration may give an indication of the inflammatory status ([@B31]). In this way, it has been hypothesized that PBMT applied before or after exercise sessions may alter these inflammatory responses due to a decreased effect of reactive oxygen and nitrogen species on cell membranes ([@B32]), increased activity of satellite cells ([@B7]; [@B34]), and increased ATP levels ([@B19]), resulting in better inflammation control and resolution.

[@B18] reported evidence of the supposed effect of PBMT on inflammation, which is supported mainly by animal model studies and *in vitro* assay results, focusing predominantly on rehabilitation. Among the few studies that investigated systemic inflammation after exercise with humans, [@B36] verified only trivial to moderate effect sizes of PBMT on IL-10, IL-1β, and TNFα in young athletes after water polo training sessions, while [@B4] verified a reduction only in IL-6 blood concentration after exercise-induced muscle damage. Therefore, it is clear that there is little evidence to support the beneficial effect of PBMT on inflammation triggered by exercise in humans and our findings indicate that when performed after high-intensity efforts, PBMT as applied in the present investigation has no significant effect on systemic inflammation (see Figure [2](#F2){ref-type="fig"}).

Decreases in blood CK concentration through PBMT is well reported in the literature ([@B4]; [@B13]) while its effect on LDH has been little investigated. Although there is no specific evidence that this mechanism actually occurs, decreases in blood CK and LDH concentrations are often related to the supposed effect of PBMT on hydroxyl radical production in muscle cells, thus reducing the damage caused in the sarcolemma and extravasation of intracellular content to the blood flow ([@B18]). However, in the present study, PBMT was not able to decrease CK and LDH blood concentrations, and neither were the CWI and AR which presented similar results to PBMT. It should be noted that our results were consistent (i.e., neither damage marker changed) and corroborate with other investigations that also did not verify changes in LDH concentration using PBMT ([@B12]; [@B36]).

The conflicting results in the literature may be explained by the different doses or energy used ([@B18]). In this way, many authors have made efforts to clarify the dose response effect of PBMT on exercise performance ([@B16]) and muscle recovery indices ([@B4]), however, the optimal dose is still unclear. In the present investigation a dose of 600 J was applied, which is higher than other recent studies ([@B4]; [@B36]). However, considering that several lower limb muscles are active during cycling ([@B24]), and that several application points were required to radiate the entire area, our doses were high mainly due to the application area. Therefore, when the dose per diode irradiation area was relativized the values were ≈ 1.5--4.5 J/cm^2^, close to the dose proposed by [@B18] for decreasing muscle damage (≈ 1.0--2.5 J/cm^2^).

Recent studies have observed beneficial effects of PBMT on lower and upper limb isometric maximum voluntary contraction ([@B4]; [@B13]) and upper limb one-repetition maximum tests ([@B17]) after exercise-induced damage protocols. However, in the present study there were no significant effects of PBMT on CWJ performance compared to C~PLA~, G~CWI~, and G~AR~. These results are in agreement with our inflammatory marker findings, which may produce loss in muscle performance ([@B30]). In the present study CMJ was used due to its efficacy to detect performance loss after high-intensity exercise sessions ([@B11]) and the insignificant effect of the jump, a brief effort, on muscle damage parameters.

In the present study, PBMT was not able to decrease DOMS after the double SIT while CWI and AR were not better than PBMT. Therefore, the results of the present study agree with our findings on inflammation, muscle damage, and performance. However, our results do not corroborate with recent studies that verified beneficial effects using PBMT or when associating PBMT with cryotherapy ([@B15]; [@B13]). It is worth mentioning that the cryotherapy method performed by these authors had no accurate temperature control (ice bag intervention). [@B26] in a recent review verified that CWI effectiveness on DOMS is dependent on the temperature (≈ 11--15°C). Therefore, more studies with humans and a well-controlled CWI temperature are necessary to clarify these conflicting results.

The main limitation of the present study is that muscle biopsies were not performed to determine intramuscular recovery parameters. However, in view of the number of blood collections (i.e., 11 in part-I and 6 in part-II) this type of procedure proved unfeasible.

Therefore, our results indicate that PBMT use after acute high-intensity efforts has no effect on muscle recovery. In addition, although the literature suggests the potential changes generated by CWI on muscle recovery mainly due to decreased DOMS ([@B26]), in the present investigation the CWI was not different to PBMT in any recovery index. Similarly, although AR is a popular recovery method in sports routines ([@B5]), this method also was not different from PBMT, which had no effect on recovery. However, it should be mentioned that some findings of the present study do not agree with previous studies, providing evidence that further studies on this same theme are needed to elucidate the real effects of PBMT.

In summary, PBMT had no effect on inflammation, muscle damage, CMJ performance, or DOMS and was not better than CWI or AR on these recovery indices.
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###### 

Performance parameters and lactate kinetics concentration before, during and after the double SIT session. SIT, sprint interval training; BW, bout work; PP, peak power; Wingate test; TW, total work; PP, peak power; MP, mean power; C~PBMT~, photobiomodulation therapy condition; C~PLA~, placebo condition.
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Click here for additional data file.

###### 

Performance parameters and lactate kinetics concentration before, during and after the double SIT session. SIT, sprint interval training; BW, bout work; PP, peak power; Wingate test; TW, total work; PP, peak power; MP, mean power; C~PBMT~, condition photobiomodulation therapy; G~CWI~, group submitted to cold-water immersion; G~AR~, group submitted to active recovery.
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Click here for additional data file.

###### 

Main time effect of blood concentration of IL-10^Δ%^, TNFα^Δ%^, CK^Δ%^, and LDH^Δ%^ (mean ± SD) in part-I and part-II. IL-10^Δ%^, interleukin 10 expressed as percentage difference to baseline; TNFα^Δ%^, tumor necrosis factor alpha expressed as percentage difference to baseline; CK^Δ%^, creatine kinase expressed as percentage difference to baseline; LDH^Δ%^, lactate dehydrogenase expressed as percentage difference to baseline. ^a^*p* \< 0.05 compared with 0.5-h. ^c^*p* \< 0.05 compared with 24-h. ^d^*p* \< 0.05 compared with 48-h. ^e^*p* \< 0.05 compared with 72-h.

###### 

Click here for additional data file.

###### 

Main time effect of DOMS^Δ^ performance and CMJ^Δ^ (mean ± SD) in part-I and part-II. DOMS^Δ^, delay onset muscle soreness expressed as difference to baseline; CMJ^Δ^, countermovement jump performance expressed as difference to baseline. ^d^*p* \< 0.05 compared with 48-h. ^e^*p* \< 0.05 compared with 72-h.

###### 

Click here for additional data file.

###### 

Blood concentration of IL-10, TNFα, CK, and LDH (mean ± SD) expressed in absolute values for C~PBMT~ and C~PLA~. IL-10, interleukin 10; TNFα, tumor necrosis factor alpha; CK, creatine kinase; LDH, lactate dehydrogenase; CPBMT, photobiomodulation therapy condition; CPLA, placebo condition; Df, degrees of freedom.

###### 

Click here for additional data file.

###### 

Blood concentration of IL-10, TNFα, CK, and LDH (mean ± SD) expressed in absolute values and the effect size of C~PBMT~, G~AR~, and G~CWI~ at baseline, 30 min, 1, 24, 48, and 72 h. L-10, interleukin 10; TNFα, tumor necrosis factor alpha; CK, creatine kinase; LDH, lactate dehydrogenase; CPBMT, photobiomodulation therapy condition; GCWI, group submitted to cold-water immersion intervention; GAR, group submitted to active recovery; Df, degrees of freedom.

###### 

Click here for additional data file.

###### 

Raw data of inflammation and muscle damage markers, delayed onset muscle soreness, and countermovement jump performance.

###### 

Click here for additional data file.
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:   creatine kinase concentration percentage of difference to baseline

CMJ

:   countermovement jump

CMJ^Δ^

:   countermovement jump height normalized by baseline

C~PBMT~

:   photobiomodulation therapy condition

C~PLA~

:   placebo condition

CWI

:   cold-water immersion
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:   delay onset muscle soreness

DOMS^Δ^

:   delay onset muscle soreness perception normalized by baseline

G~AR~

:   active recovery group
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:   cold-water immersion group
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:   photobiomodulation therapy
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:   tumor necrosis factor-α

TNFα^Δ%^

:   tumor necrosis factor-αconcentration percentage of difference to baseline
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VAS

:   visual analog scale
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